MYRBETRIQ Drug Patent Profile

Which patents cover Myrbetriq, and when can generic versions of Myrbetriq launch?

Myrbetriq is a drug marketed by Apgdi and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-three patent family members in twenty-five countries.

The generic ingredient in MYRBETRIQ is mirabegron. There are nineteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the mirabegron profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Myrbetriq

A generic version of MYRBETRIQ was approved as mirabegron by LUPIN on September 28^th, 2022.

Summary for MYRBETRIQ

International Patents:	53
US Patents:	5
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	52
Patent Applications:	536
Drug Prices:	Drug price information for MYRBETRIQ
Drug Sales Revenues:	Drug sales revenues for MYRBETRIQ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MYRBETRIQ
What excipients (inactive ingredients) are in MYRBETRIQ?	MYRBETRIQ excipients list
DailyMed Link:	MYRBETRIQ at DailyMed

See drug prices for MYRBETRIQ

See drug sales revenues for MYRBETRIQ

Recent Clinical Trials for MYRBETRIQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Il-Yang Pharm. Co., Ltd.	Phase 2
Seoul National University Hospital	Phase 2
Cedars-Sinai Medical Center	Phase 2

See all MYRBETRIQ clinical trials

Pharmacology for MYRBETRIQ

Drug Class	beta3-Adrenergic Agonist
Mechanism of Action	Adrenergic beta3-Agonists Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for MYRBETRIQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MYRBETRIQ	Extended-release Tablets	mirabegron	50 mg	202611	6	2016-06-28

US Patents and Regulatory Information for MYRBETRIQ

MYRBETRIQ is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012	AB	RX	Yes	Yes					Y
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012	AB	RX	Yes	Yes					Y
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012	AB	RX	Yes	Yes					Y
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012	AB	RX	Yes	Yes					Y

Expired US Patents for MYRBETRIQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012

EU/EMA Drug Approvals for MYRBETRIQ

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Astellas Pharma Europe B.V.	Betmiga	mirabegron	EMEA/H/C/002388Symptomatic treatment of urgency.Increased micturition frequency and / or urgency incontinence as may occur in adult patients with overactive-bladder syndrome.	Authorised	no	no	no	2012-12-20

International Patents for MYRBETRIQ

When does loss-of-exclusivity occur for MYRBETRIQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Croatia

Cyprus

Denmark

European Patent Office

Japan

Poland

Portugal

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MYRBETRIQ around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2009300752
Brazil	PI0919466
Canada	2740342
China	102170878

Supplementary Protection Certificates for MYRBETRIQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1559427	C300599	Netherlands		PRODUCT NAME: MIRABEGRON EN ZOUTEN ERVAN; REGISTRATION NO/DATE: EU/1/12/809/001-014 20121220
1559427	CA 2013 00028	Denmark
1559427	92218	Luxembourg		PRODUCT NAME: MIRABEGRON OU UN DE SES SELS
1559427	13C0032	France		PRODUCT NAME: MIRABEGRON ET SES SELS; REGISTRATION NO/DATE: EU/1/12/809/001 20130107

MYRBETRIQ (mirabegron) Market Dynamics and Financial Trajectory: Exclusivity, Competition, Revenue Outlook, and Patent/IP Risk

Last updated: July 21, 2026

Executive summary: MYRBETRIQ (mirabegron) has shifted from protected brand growth to a more contested market as payers, formularies, and competitive dynamics have tightened. The product’s near-term revenue trajectory is shaped by (1) brand utilization under contracting and substitution pressures, (2) the pace of generic and authorized-availability changes for mirabegron (including retail mix effects), (3) persistence of MYRBETRIQ’s clinical differentiation and dosing convenience, and (4) the scope and strength of remaining patent and regulatory exclusivities tied to specific dosage forms and strengths. Financial outcomes are therefore less dependent on blockbuster lifecycle mechanics and more dependent on net price, channel mix, and how quickly lower-cost entries penetrate Medicare Part D and commercial formularies in overactive bladder (OAB) and related indications.

---

What is MYRBETRIQ (mirabegron) and how is it used in overactive bladder?

MYRBETRIQ is a beta-3 adrenergic receptor agonist indicated for OAB. In practice, it is used to reduce urgency, frequency, and urge urinary incontinence. Across payer formularies, it is positioned as an alternative to antimuscarinics for patients who have anticholinergic side-effect concerns.

What patient segments drive demand?

• Patients newly treated for OAB with preference to avoid cognitive or dry-mouth burden typical of antimuscarinics.
• Patients who discontinue antimuscarinics due to tolerability.
• Patients in combination pathways (behavioral therapy plus pharmacotherapy; and in some settings co-therapy with other agents depending on provider preference).

How do dosing formats affect prescribing?

Market outcomes for MYRBETRIQ are sensitive to:

• Once-daily convenience (adherence).
• Availability across strengths used in real-world titration and switching.

---

How do MYRBETRIQ pricing, rebates, and payer coverage dynamics affect revenue?

Net sales trajectory for MYRBETRIQ is primarily a function of net price, which is driven by rebate structures, formulary placement, and step edits.

Key payer mechanics influencing brand retention

1. Formulary tier placement
   • When a brand drops to higher tiers or is subject to prior authorization, prescription volume tends to compress.
2. Step therapy
   • Payers may require antimuscarinic trial or documented intolerance before approving mirabegron.
3. Generic substitution pressure
   • Once lower-cost mirabegron options gain meaningful presence, pharmacy benefit managers can steer scripts via tiering and preferred alternatives.

What does “net revenue” typically reflect in this class?

For OAB therapies, net sales are often materially different from gross invoice sales due to:

• Volume rebates tied to formulary access.
• Contracting that changes after competitive entry.
• Audit and chargeback mechanics.

---

When does MYRBETRIQ lose exclusivity and how does that change market penetration?

Revenue risk accelerates when exclusivity ends and lower-cost products enter through ANDA pathways or market-authorized competition that changes pharmacy ordering behavior.

Exclusivity and entry timing: what to watch commercially

• Regulatory exclusivities: product-level exclusivity (new active ingredient) and any U.S. exclusivity extensions that may delay generic approval for certain strengths or dosage forms.
• Patent expiry: practical generic launch is often constrained by listed Orange Book patents and litigation outcomes.
• Settlement dynamics: settlements can produce “authorized generic” or delayed entry beyond the legal expiry date.

How do launch mechanics alter the cash flow curve?

When entry happens:

• Gross scripts may continue briefly as prescribers maintain therapy, but fill and switch rates usually shift quickly after PBM contracting changes.
• Channel inventory and wholesaler buy-ins can produce an early-order spike for brand (or competitor), followed by a reversion driven by pharmacy claims.

---

How strong is the patent estate for MYRBETRIQ, and which patent types matter most?

For MYRBETRIQ, the patent estate’s commercial relevance depends on which listed claims block specific generic pathways:

• Drug substance/composition of matter patents (strong but often time-limited).
• Formulation and dosage form patents (can delay generic substitutes for particular strengths).
• Method-of-use patents (can restrict certain claim designs if tied to labeled/claimed use).
• Manufacturing/process patents (usually narrower but can create design-around friction).

Patent risk hotspots for generics

• Patents covering specific extended-release characteristics or formulation details.
• Patents with claims that cover a labeled strength or release profile.
• Remaining Orange Book listings that are still enforceable at the time of generic ANDA approval.

What to expect in litigation and post-approval disputes

The commercial impact is measured by:

• Whether generics can launch immediately after court decisions.
• Whether settlements include “launch delay” terms or covenants not to sue.

---

What patents protect mirabegron formulations and extended-release versions?

Market outcomes can differ by:

• Strength (e.g., lower vs higher dose presentations).
• Dosage form details (extended-release vs other).
• Label-specific language used by competitors to claim freedom to market.

Formulation patent relevance in OAB competition

If a generic can copy dosing characteristics but faces formulation patents for specific strengths, it may:

• Launch only partial strength coverage first.
• Require later market expansion after additional legal clearance.

---

What is the Orange Book status of MYRBETRIQ and what does it imply for generic entry?

Orange Book status is the direct map of:

• Which patents are listed for the approved NDA(s),
• Their expiration dates,
• And which patents are still active during ANDA litigation windows.

How to interpret Orange Book listings for business planning

• Patents listed under “drug substance” and “drug product” typically signal higher barriers.
• The number of listed patents and their expiration distribution determine the likelihood of staggered generic launches.
• The presence of “500(b)” or related exclusivities does not stop generic competition by itself, but it changes the regulatory gating timeline.

---

Which companies are selling mirabegron as MYRBETRIQ’s competitive alternatives?

The competitive set depends on:

• Whether competitors are substituting with generics that include mirabegron across the same dosing range.
• Whether authorized generics or multi-source generic entries are active in key markets.

Competitive impacts that show up in financial statements

• Mix shift: higher share of lower-cost claims reduces average net price.
• Contract renegotiation: brand manufacturers often face steep rebate escalation or promotional adjustments to defend utilization.
• Wholesale and pharmacy ordering behavior: as generics gain shelf presence, scripts migrate even if switching is not immediate.

---

How does MYRBETRIQ compare with other OAB drugs in market share dynamics?

OAB therapy is dominated by antimuscarinics and beta-3 agonists. MYRBETRIQ competes through a mix of efficacy-tolerability positioning and payer preferences.

Key competitor classes

• Antimuscarinics: often cheaper but limited by tolerability.
• Other beta-3 agonists: where available, they can become preferred alternatives on certain formularies.
• Combination and add-on pathways: can divert volume when payers require step edits or when clinicians pursue alternative efficacy/safety tradeoffs.

What drives relative performance in real-world claims?

• Rate of persistence and adherence.
• Tolerability-driven discontinuation.
• Payer restrictions that influence time-to-therapy initiation.

---

What generic entry risks exist for MYRBETRIQ and what launch scenarios are most likely?

For brand-to-generic transitions, the most important outcome variables are:

• Whether generics have full-strength launch coverage immediately.
• Whether settlements delay certain products or certain strengths.
• Whether “skinny labels” and claim design allow prompt entry.

Launch scenarios that affect revenue magnitude

1. Single strength launch first
   • Partial substitution can keep a portion of brand share temporarily.
2. Full-strength multi-source entry
   • Usually results in accelerated decline in brand net sales.
3. Delayed entry or staggered settlements
   • Keeps brand revenues higher for longer but tends to pull forward demand during protected periods.

Market penetration ramp is rarely linear

• Early generics can have limited formulary positioning.
• As contracts refresh and PBM policies update, switching can accelerate over 6 to 18 months.

---

What litigation and Paragraph IV challenges have influenced MYRBETRIQ availability?

For MYRBETRIQ, the litigation impact is assessed by:

• Court decisions on listed Orange Book patents.
• Settlements with described launch dates and terms.
• Downstream effect on generic launch timing and authorized generic presence.

Commercially relevant litigation milestones

• Filing of ANDA paragraph IV certifications.
• Claim construction and final court decisions.
• Settlement agreements that include delayed market entry or phased launch.

---

What is the FDA regulatory status of MYRBETRIQ and how does it affect competition?

FDA status determines whether competitors can market quickly or must wait for regulatory triggers.

Regulatory mechanisms that can shape timing

• ANDA approval with respect to listed patents and the ability to launch without injunction.
• Labeling alignment and any differences that can influence payer switching behavior.

---

How has MYRBETRIQ’s financial trajectory evolved from brand peak to current phase?

A brand’s financial arc in OAB typically follows:

• Early growth on differentiation and prescriber adoption,
• Peak as payer penetration expands,
• Then deceleration as competition and contracting tighten.

What financial drivers matter most during late lifecycle

• Net pricing compression (rebates and discounts).
• Volume share erosion due to multi-source availability.
• Higher market spending required to defend utilization.
• Shifts to alternative therapies by prescribers and by payer rules.

Revenue exposure profile

For MYRBETRIQ, exposure is strongest in:

• Markets where formulary placement is most competitive.
• Strengths where generic substitution is easiest.
• Patients treated chronically who are more likely to switch when a plan changes preferred status.

---

How does MYRBETRIQ’s financial trajectory compare with other mid-to-late lifecycle urology brands?

In urology, brands with a single dominant mechanism often experience:

• Steep net price compression after generic penetration,
• More gradual volume erosion if clinical practice favors continuity,
• Shorter tail periods when payers adopt preferred generic substitution.

Comparison vector for business planning

• Time from first generic availability to broad PBM preferred placement.
• Reduction in brand share and sustained decline in net price after contract renegotiation.
• Any retention effect from patient tolerance and adherence.

---

Key business implications for licensing, R&D, and portfolio strategy

For licensing and BD

• Evaluate which specific strengths and dosage forms face fewer remaining barriers because these determine the revenue ceiling in a license deal or co-promotion scenario.
• Contracting defensibility depends on whether MYRBETRIQ remains “preferred” post-entry.

For R&D

• The market will continue favoring dosing convenience and tolerability, so R&D differentiation should target outcomes that matter to payers: adherence, persistence, and discontinuation rates.

For litigation planning

• Focus on the most enforceable Orange Book patents with remaining legal life.
• Tie litigation strategy to expected generic launch scenarios rather than patent list count alone.

---

Key Takeaways

• MYRBETRIQ’s revenue trajectory is increasingly driven by net price and formulary access rather than pure clinical uptake.
• Generic and authorized competition dynamics are the principal accelerants of cash flow decline, with substitution intensity shaped by PBM contracting and strength-level launch coverage.
• Patent estate strength matters most when it blocks full-strength generic entry at once; staggered or partial coverage scenarios can slow revenue erosion.
• Financial outcomes depend on how quickly competing products become preferred at the pharmacy level and how consistently prescribers maintain mirabegron therapy under payer pressure.

---

FAQs

1) What happens to MYRBETRIQ sales when generics enter only certain strengths first?
Brand decline typically slows initially, but the magnitude depends on PBM policy and how quickly prescribers switch within the same prescribing habit.

2) How do step edits for OAB therapies change mirabegron prescribing?
They can delay initiation and reduce switch-to-brand behavior, especially when payer requires prior antimuscarinic exposure or documented intolerance.

3) Do formulation differences affect generic substitution for MYRBETRIQ?
Yes. If patents protect strength-specific or release-profile attributes, generics may launch incompletely and expand later.

4) What is the most common financial pattern after generic entry for an OAB brand?
Net price compression usually hits fast through rebates and contracting, while volume erosion and persistence-driven switching often follow over ensuing quarters as pharmacy claims normalize.

5) How should a portfolio investor model MYRBETRIQ revenue in a late lifecycle year?
Use scenarios tied to (a) the speed of PBM preferred placement for competitors and (b) whether entry is multi-source and full-strength versus delayed or partial.

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (accessed via FDA databases).
2. FDA labeling for MYRBETRIQ (mirabegron) and relevant OAB indication information (accessed via Drugs@FDA).
3. FDA ANDA approval history and related submissions for mirabegron (accessed via FDA databases).

DrugChatter Q&A for MYRBETRIQ

When does myrbetriq go generic?
When does patent expire for myrbetriq?
When will myrbetriq come off patent?
Is there a generic myrbetriq?
Myrbetriq granules discontinued?